Therapeutic Options in Hypertrophic Cardiomyopathy View PDF

^*Lothar Faber
Department Of Cardiology, Heart And Diabetes Centre North Rhine – Westphalia, Ruhr-University Bochum, Germany

^*Corresponding Author:

Lothar Faber
Department Of Cardiology, Heart And Diabetes Centre North Rhine – Westphalia, Ruhr-University Bochum, Germany
Email:lfaber@hdz-nrw.de

Published on: 2015-01-21

Abstract

Hypertrophic cardiomyopathy (HCM) is one of the more common hereditary cardiac conditions. Several hundreds of mutations in genes coding for sarcomeric or energy metabolism proteins have been found to be associated with the phenotype. Myocardial disarray and fibrosis are the prominent histological findings of the disease. A more common (70%) obstructive (HOCM) has to be distinguished from the less common (30%) non-obstructive phenotype (HNCM). Symptoms include exercise limitation due to dyspnea or angina pectoris, palpitations, or dizziness.

Keywords

Hypertrophic obstructive cardiomyopathy; Percutaneous septal ablation, Myectomy, Risk stratification, Sudden cardiac death, ICD, HOCM, HCM, HNCM

Introduction

One of the first descriptions of what is nowadays labeled as hypertrophic cardiomyopathy (HCM, 1-62) was written in 1958 by the british pathologist Teare who suspected a cardiac neoplasia